Program
camlipixant
Also written as “BLU-5937”, “Camlipixant” and “BLU-5937 ER”.
In GlaxoSmithKline's pipeline, P2X3 receptor antagonist
. Its studies are mostly in Cough · Chronic Cough · Irritable Bowel Syndrome · Dermatitis, Atopic, led by GlaxoSmithKline.
Furthest: phase 3, since Oct 18, 202216 company-led studies, 3 open or runningNext primary completion: Mar 9, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 163 open or running | phase 3since Oct 18, 2022 | Aug 15, 2018 | Mar 9, 2027phase 2 · NCT07519395 |
- Named in GlaxoSmithKline’s own pipeline as
camlipixant GSK5464714
, phase 2, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 15, 2018First study: phase 1 study in CoughFirst studyNCT03638180 · 90 enrolled · Canada
- Jun 6, 2019Phase 2 study in Chronic CoughNCT03979638 · 68 enrolled · United States, United Kingdom
- Dec 9, 20202 phase 2 studiesNCT04678206, NCT04693195
- Feb 11, 2022Phase 1 study in HealthyNCT05244759 · 6 enrolled · United Kingdom
- Oct 3, 2022Phase 1 study in CoughNCT05570539 · 30 enrolled · United Kingdom
- Oct 18, 20222 phase 3 studies in CoughNCT05600777, NCT05599191
- Jun 2, 2023Phase 1 study in CoughNCT05899829 · 42 enrolled · Canada
- Jul 17, 2023Phase 1 study in CoughNCT05959447 · 45 enrolled · Canada
- Nov 27, 2023Phase 1 study in HealthyNCT06179537 · 34 enrolled · United Kingdom
- Jan 16, 2024Phase 1 study in CoughNCT06222892 · 32 enrolled · United States
- Jul 5, 2024Phase 1 study in CoughNCT06497517 · 14 enrolled · United States
- Apr 2, 2026Phase 2 study in Irritable Bowel SyndromeNCT07519395 · 420 planned · United States
- Jun 10, 2026Phase 3 study in Chronic CoughNCT07650084 · 75 planned · China
- Jun 29, 2026Phase 1 study in CoughNCT07684586 · United Kingdom
Ahead
- Mar 9, 2027Primary completion: phase 2 study in Irritable Bowel SyndromeNCT07519395
- Aug 27, 2027Primary completion: phase 3 study in Chronic CoughNCT07650084
TargetBeta
“P2X3 receptor antagonist”the company's pipeline, read by Claude · source
“P2X purinoceptor 3 antagonist”ChEMBL 37, by rule
Other programs on P2RX3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| TCR1672 | Sino Biopharmaceutical | phase 2 | 1 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07684586Cough · United Kingdom | 1 | Withdrawn | Aug 27, 2027 | 0 |
| NCT07650084Chronic Cough · China | 3 | Recruiting | Aug 27, 2027 | 75 |
| NCT07519395Irritable Bowel Syndrome · United States | 2 | Recruiting | Mar 9, 2027 | 420 |
| NCT06497517Cough · United States | 1 | Completed | Aug 22, 2024 | 14 |
| NCT06222892Cough · United States | 1 | Completed | Dec 17, 2024 | 32 |
| NCT06179537Healthy · United Kingdom | 1 | Completed | Oct 22, 2021 | 34 |
| NCT05959447Cough · Canada | 1 | Completed | Oct 13, 2023 | 45 |
| NCT05899829Cough · Canada | 1 | Completed | Aug 8, 2023 | 42 |
| NCT05600777Cough · United States, Australia, Canada and more | 3 | Active, not recruiting | Jun 10, 2026 | 997 |
| NCT05599191Cough · United States, Argentina, Belgium and more | 3 | Completed | Dec 17, 2025 | 957 |
| NCT05570539Cough · United Kingdom | 1 | Completed | May 2, 2024 | 30 |
| NCT05244759Healthy · United Kingdom | 1 | Completed | Sep 23, 2020 | 6 |
| NCT04693195Dermatitis, Atopic · United States, Canada | 2 | Completed | Oct 4, 2021 | 142 |
| NCT04678206Chronic Cough · United States, Canada, Czechia and more | 2 | Completed | Oct 21, 2021 | 310 |
| NCT03979638Chronic Cough · United States, United Kingdom | 2 | Terminated | Apr 23, 2020 | 68 |
| NCT03638180Cough · Canada | 1 | Completed | Oct 25, 2018 | 90 |
How it is read
Names in the registry
- “BLU-5937”, 8 entries
- “Camlipixant”, 5 entries
- “BLU-5937 ER”, 1 entry
- “GSK5464714- Camlipixant”, 1 entry
- “[14C]-BLU-5937”, 1 entry
Conditions, from the studies’ own filings
- Cough, 7 studies
- Chronic Cough, 5 studies
- Irritable Bowel Syndrome, 1 study
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.